InSite Vision Completes DOUBle Phase 3 Clinical Study of AzaSite Plus™ and DexaSite™ for the Treatment of Blepharitis

ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB: INSV) today announced that the last patient has completed dosing and evaluation in the DOUBle Phase 3 clinical trial of AzaSite Plus™ and DexaSite™ for the treatment of blepharitis. There are more than 34 million blepharitis sufferers in the United States who currently have no FDA-approved drug therapies available to them. The DOUBle (Dual Ophthalmic agents Used in Blepharitis) study enrolled more than 900 patients with moderate-to-severe blepharitis in a four-arm trial designed to evaluate the efficacy and safety of both product candidates simultaneously. InSite Vision expects that top-line data from the DOUBle Phase 3 clinical trial will be available in the second quarter of 2013.